International Society for Cutaneous Lymphomas

ISCL Cutaneous Lymphoma Symposium

At the 2018 International Investigative Dermatology (IID) Meeting
Wednesday/May 16, 2018
1:30pm-4:30pm
Orlando, Florida, USA
Rosen Shingle Creek Resort; Meeting Room: Panzacola G2/F3/F4

ISCL Program Committee: Joan Guitart-CHAIR, Martine Bagot, Larisa Geskin, Sam Hwang, Ramon Pujol, Gary Wood

Refining and Redefining Blood Involvement in MF/SS

1:30-1:40 Welcome & Introduction
   The American Clinician’s Perspective
   Joan Guitart, MD, FAAD, Program Chair and ISCL President
   Chief of Dermatopathology in the Department of Dermatology; Professor of Dermatology and Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

1:40-2:25 State-of-the-Art Lecture: The Hematopathologist’s Perspective
   Fiona E. Craig, MD, Professor of Laboratory Medicine and Pathology, Mayo Clinic Arizona, USA

2:25-2:35 The European Perspective
   Julia Scarisbrick, MBChB, FRCP, MD, Consultant Dermatologist, University Hospital Birmingham, U.K.

2:35-2:40 Q&A and Discussion

2:40-2:45 ISCL General Membership Business Meeting

2:45-3:00 Coffee Break

Cutaneous Lymphoma Foundation Young Investigator Award and Presentation

3:00-3:15 Skin Commensals as Instigators of Cutaneous T Cell Lymphoma, Carina Dehner

Abstracts Presentations

8 minutes for presentation + 2 minutes for Q&A and change of speaker

3:15-3:25 BET inhibition markedly inhibits CTCL cell viability and is synergistically potentiated by BCL2 or HDAC inhibition, Sa Rang Kim, #452

3:25-3:35 Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma, Lei Zhao, #400

3:35-3:45 Gentian violet induces pro-apoptotic and anti-proliferative effects in cutaneous T-cell lymphoma (CTCL): Preclinical studies, Jianqiang Wu, #423
Targeting the vitamin B6 pathway as a novel therapeutic strategy for cutaneous T-cell lymphoma, Cynthia Chen, #163

Sézary syndrome patient-derived xenografts for 21-color flow cytometry immunophenotyping and CART cell therapeutic testing, Karl Staser, #441

PUVA and maintenance treatment in mycosis fungoides: Systemic aberrant cytokine expression is a predictor of outcome, Pablo Vieyra-Garcia, #579

Successful identification of copy number variations using next generation sequencing with a tumour panel in plaque/tumour mycosis fungoides, J Yoo, #146

Differences in the miRNA expression profiles of erythrodermic Mycosis Fungoides and Sézary Syndrome, Anne Hald Rittig, #473

Visit www.cutaneouslymphoma.org for more information about the ISCL and membership!